Lucicebtide is under clinical development by Sapience Therapeutics and currently in Phase II for Sarcomas. According to GlobalData, Phase II drugs for Sarcomas have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lucicebtide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lucicebtide overview
Lucicebtide (ST-101) is under development for the treatment of recurrent glioblastoma multiforme (rGBM), newly diagnosed glioblastoma multiforme (nGBM), locally advanced or metastatic breast cancer, metastatic castration-resistant prostate cancer (mCRPC), metastatic melanoma like cutaneous and mucosal melanoma, hepatocellular carcinoma, esophageal adenocarcinoma, uveal melanoma, signet ring adenocarcinoma, small bowel adenocarcinoma, abdominal sarcoma, glioma and lung cancer. It is administered through intravenous route. The therapeutic candidate is a synthetic peptide designed to contain a cell-penetrating domain and a dominant-negative form of the human transcription factor ATF5. It acts by targeting CCAAT/enhancer binding protein beta (C/EBPB).
The therapeutic candidate was under development for the treatment of acute myeloid leukemia, medulloblastoma, triple negative breast cancer (TNBC), pediatric neuro-oncology such as glioblastoma multiforme and neuroblastoma.
Sapience Therapeutics overview
Sapience Therapeutics is a biotechnology company that focuses on developing peptide-based cancer therapeutics. Its main activities focus on the research and development of first-in-class peptide antagonists targeting oncogenic and immune-modulating drug targets. The company’s products include The company develops products such as ST101, ß-Catenin Antagonist, cJun Antagonist, FoxP3 Antagonist and others. Sapience Therapeutics’ ST101 products are used in the treatment of breast cancer, melanoma, prostate cancer, GBM, lung cancer and AML. Its products are primarily used in the healthcare industry, specifically in oncology, to treat various forms of cancer. Sapience Therapeutics is headquartered in Tarrytown, New York, the US.
For a complete picture of Lucicebtide’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
